AMLX vs CRNX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AMLX and CRNX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AMLX and CRNX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Amylyx Pharmaceuticals develops treatments for neurodegenerative and endocrine conditions with few or no approved options. Its lead program is avexitide, a GLP-1 antagonist being tested in adults with post-bariatric hypoglycemia (PBH), a condition where people who have had Roux-en-Y gastric bypass surgery experience severe blood-sugar crashes. The registrational Phase 3 LUCIDITY trial enrolled 78 participants across a 16-week blinded period and met its pre-specified primary endpoint: a 55% reduction in Level 2 and Level 3 hypoglycemic events (p=0.000003). It also met secondary endpoints on Level 2 events, Level 3 events, and continuous glucose-monitoring outcomes, and avexitide was generally safe and well tolerated, consistent with earlier trials. All eligible patients moved into the open-label extension. Amylyx plans to present the topline data at ObesityWeek 2026 and to submit a New Drug Application before year-end 2026, with management discussing a possible 2027 launch. Behind it sit AMX0035 in Wolfram syndrome (a focused registrational Phase 3 was guided for the second half of 2026 after extended Phase 2 HELIOS data showed trends in pancreatic function and vision stabilization), AMX0114 in ALS (Phase 1 LUMINA data reported as safety-supportive), and AMX0318 in IND-enabling studies.

Full AMLX guide

Crinetics Pharmaceuticals is a San Diego-based biopharmaceutical company that discovers and develops oral small-molecule therapies for endocrine diseases and endocrine-related tumors. Its first marketed product, PALSONIFY (paltusotine), is a non-peptide, once-daily oral selective somatostatin receptor ligand approved by the FDA in September 2025 and by European regulators in 2026 for acromegaly, a condition long treated with monthly injectable drugs. Behind PALSONIFY sits a deep pipeline of 10-plus programs, led by atumelnant (in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome) and CRN09682, a drug conjugate aimed at neuroendocrine tumors, plus earlier programs across Graves' disease, hyperparathyroidism, polycystic kidney disease, and other endocrine indications.

Full CRNX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AMLX drivers: From LUCIDITY data to an FDA filing; A market with no approved therapy.
• CRNX drivers: Vertex acquisition completed at $85 cash; PALSONIFY launch, now inside Vertex.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The concentration risk remains the dominant one: avexitide now carries nearly all of the equity value, and a positive 78-patient trial still leaves FDA review risk, label risk, and the possibility of requests for more data. For CRNX, with the merger closed, the deal-break risk that dominated the stock through the summer is gone, and former CRNX holders no longer carry any Crinetics-specific risk once they have received the $85.00 cash payment.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AMLX if you believe its drivers more; CRNX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AMLX and CRNX guides.

AMLX. Standard valuation multiples do not apply here because there is no revenue and no path to profitability without an approval. After the positive LUCIDITY result, the market capitalization of about $3.35 billion (October 16, 2026) sits on top of about $251 million of cash and a trailing loss near $152 million, so most of the value is the market's view of avexitide's approval odds and launch potential. The 11 analysts covering the stock have an average target near $43, and the Q3 2026 report on November 5 will update the cash line and filing timeline.

CRNX. Before the July 2026 announcement, Crinetics carried a market capitalization of roughly $4.5 billion despite minimal revenue, a valuation typical of a rare-disease biotech pricing in an early launch and pipeline optionality. Vertex's $85.00 cash offer, about $10 billion in equity value, set the final price, and the stock closed at $84.95 on its last trading day before the September 1, 2026 closing. Standard earnings multiples were never meaningful here, and with the shares delisted there is no live valuation left to measure.

Headline figures (approximate, October 2026): AMLX shows product revenue None (Relyvrio withdrawn in 2024; consensus ~$28M for 2027), cash and equivalents ~$250.8M (June 30, 2026), cash runway Guided into 2028, net loss (ttm) ~$152M (EPS ~-$1.41); CRNX shows acquisition price (vertex, cash, paid sep 1, 2026) $85.00/share, deal equity value ~$10B, last close before delisting (aug 31, 2026) ~$84.95, revenue (q2 2026) ~$25.1M.

AMLX and CRNX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AMLX and CRNX exposure against your real portfolio. It is not an investment adviser.